 Longeveron Inc NASDAQ: LGVN is a clinical biotech firm that develops cellular therapies to treat life-threatening and aging-related conditions. It announced that it had received approval from the FDA for the RPD Rare Pediatric Disease designation for its Lomecel-B to treat Hypoplastic Left Heart Syndrome. 